Systematic evaluation of efficacy and safety of Songling Xuemaikang Capsules in treatment of essential hypertension.
10.19540/j.cnki.cjcmm.20200401.502
- Author:
Gen-Hao FAN
1
;
Zuo-Ying XING
1
;
Meng-Lin LIU
1
;
Yan CHEN
1
;
Yi-Pei AN
1
;
Zhao-Qi CHEN
2
;
Yong-Xia WANG
1
Author Information
1. Henan University of Traditional Chinese Medicine Zhengzhou 450000, China.
2. Department of Traditional Chinese Medicine, Henan People's Hospital Zhengzhou 450000, China.
- Publication Type:Meta-Analysis
- Keywords:
Meta-analysis;
Songling Xuemaikang Capsules;
efficacy;
essential hypertension;
safety;
systematic evaluation
- MeSH:
Angiotensin Receptor Antagonists;
Angiotensin-Converting Enzyme Inhibitors;
Capsules;
Drugs, Chinese Herbal;
Essential Hypertension/drug therapy*;
Humans
- From:
China Journal of Chinese Materia Medica
2021;46(2):467-477
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the efficacy and safety of Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. PubMed, VIP, CNKI, Wanfang and other databases were retrieved from the establishment of the database to February 2020 for clinical randomized controlled trial(RCT) about Songling Xuemaikang Capsules combined with conventional Western medicine in the treatment of essential hypertension. The literatures were screened out according to the inclusion criteria, and RevMan 5.3 software was used for Meta-analysis. A total of 3 100 patients in 27 RCTs were enrolled. According to Meta-analysis, Songling Xuemaikang Capsules combined with conventional Western medicine could effectively reduce systolic blood pressure(MD=-7.88,95%CI[-9.68,-6.08],P<0.000 01) and diastolic blood pressure(MD=-7.85, 95%CI[-9.07,-6.62], P<0.000 01), triglyceride(MD=-0.46, 95%CI[-0.66,-0.26], P<0.000 01) and total cholesterol(MD=-0.92, 95%CI[-1.49,-0.35], P=0.001), but increase HDL cholesterol(MD=0.51, 95%CI[0.28, 0.73], P<0.000 01), with a better effect than the Western medicine group alone. The results of LDL-C analysis showed that there was no significant difference between the two groups(MD=-0.91, 95%CI[-1.82, 0.01], P=0.05). The subgroup analysis suggested that reduced systolic blood pressure may be related to the use of ARB. There was a close correlation between CCB drugs and the decrease of diastolic blood pressure. In addition, there was no significant difference in the compliance and the incidence of adverse reactions. Clinical application of Songling Xuemaikang Capsules combined with Western medicine in the treatment of patients with essential hypertension has clear efficacy and certain safety. More clinical randomized controlled trials are needed for verification in the future.
